Lipid Controls
TARGETMOL CHEMICALS INC DLin-KC2-DMA 10MG
Also available in 2 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg and bulk. Please contact Fisher for quotes. DLin-KC2-DMA is a cation that can be used for siRNA delivery and is also an ionizable lipid. DLinKC2-DMA can bind to LNP and enable siRNA-mediated GAPDH gene silencing. Purity 97.74%
Avanti Polar Lipids EGG PHOSPHATIDYLCHOLINE 200MG
L- alpha -Phosphatidylcholine (Egg, Chicken). 97281-44-2
Avanti Polar Lipids 18:1 PS (DOPS) | 90693-88-2 | MFCD00133436 | 200mg
18:1 PS (DOPS) | Putity: >99% | MW: 810.025 | 90693-88-2 | MFCD00133436 | 200mg
![eMolecules Medchem Express / DLin-K-C3-DMA / 5mg / 705861090 / HY-145225 / / 1217306-46-1 / [null] / 656.137 / C44H81NO2](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502475135.JPG-250.jpg)
eMolecules Medchem Express / DLin-K-C3-DMA / 5mg / 705861090 / HY-145225 / / 1217306-46-1 / [null] / 656.137 / C44H81NO2
Medchem Express / DLin-K-C3-DMA / 5mg / 705861090 / HY-145225 / / 1217306-46-1 / [null] / 656.137 / C44H81NO2
Cayman Chemical Lyso-PAF C-16 5mg
Lyso-PAF C-16 can be formed by either the action of PAF-AH on PAF C-16,{2626} or by the action of a CoA-independent transacylase on 1-O-hexadecyl-2-acyl-glycerophosphocholine.{240,2098} Lyso-PAF C-16 is a substrate for either PAF C-16 formation by the remodeling pathway{939} or selective acylation with arachidonic acid by a CoA-independent transacylase.{2101}
Avanti Polar Lipids DIFFERENTIAL ION MOBILITY SYS
Differential Ion Mobility System Suitability Synthetic Standard Mixture. Mixture contains 1mg/ml of each lipid below (0.25mg/ml PI), 0.5ml per vial in chloroform: methanol (1:1). We recommend purchasing Bovine Heart Extract as an accompanying product.
eMolecules Medchem Express / DPPC / 10mg / 437899074 / HY-109506 / / 63-89-8 / MFCD00036903 / 734.053 / C40H80NO8P
Medchem Express / DPPC / 10mg / 437899074 / HY-109506 / / 63-89-8 / MFCD00036903 / 734.053 / C40H80NO8P
Cayman Chemical DLIn-MC2-DMA 1mg
An ionizable cationic lipid; has been used in the formation of LNPs; LNPs containing DLin-MC2-DMA and encapsulating siRNA targeting mRNA encoding FVII reduce hepatic levels of FVII in mice (ED50 = 0.6 mg/kg)
Medchemexpress LLC Dspe-peg2000-cys-srnlidc (disulfide bridge cys1-cys8) | 95.2% | 2000 Da (average) | 10 MG
DSPE-PEG2000-Cys-SRNLIDC is a lipid-PEG conjugate that links a DSPE lipid to a cyclic SRNLIDC peptide through a PEG2000 spacer containing a disulfide bridge (Cys1-Cys8). It is provided for research use to functionalize lipid nanoparticles or liposomes for targeting and to enable disulfide-triggered intracellular release. PEGylation improves colloidal stability and compatibility with aqueous formulations.
- Enables surface functionalization of lipid nanoparticles.
- Provides disulfide-mediated intracellular release of linked cargo.
- PEG2000 spacer enhances colloidal stability and circulation.
- Supplied with high reported purity for research applications.
- Soluble in DMSO for stock solution preparation.
- Recommended storage at -20°C to preserve integrity.